Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Lets find…
68,468$
-1,91%
Echtzeit-Aktienkurs Soleno Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Soleno Therapeutics Inc. Aktie
Soleno Therapeutics - FDA-Zulassung für Vykat XR markiert wichtigen Meilenstein!
Geschäftstreiber: Soleno Therapeutics (SLNO) hat sich auf die Entwicklung neuer Therapien und Medikamente für seltene Erkrankungen spezialisiert. Mit der FDA-Zulassung…
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com
Soleno Therapeutics stock falls after pricing $200 million offering…
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel…
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing…
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research,…
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company…
Soleno Therapeutics: Das Biopharmazie-Unternehmen erhält wichtige FDA-Zulassung für ein Medikaments zur Behandlung einer seltenen genetischen Störung
Soleno ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika zur Behandlung seltener Krankheiten entwickelt. Mit der FDA-Zulassung von VYKAT XR,…
Soleno Therapeutics im Pivotal-Point-Check: Stifel sieht „Blockbuster-Chance“ durch die Zulassung von Vykat XR zur Behandlung des Prader-Willi-Syndroms!
Soleno Therapeutics hat einen Meilenstein auf dem Markt für seltene Krankheiten erreicht. Die Behandlung mit Diazoxid-Cholin zielt darauf ab,…
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval
…
Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me
…
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
…
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The companys Prader-Willi treatment inched closer to FDA approval.…
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients
…
Soleno Therapeutics CFO sells over $298k in company stock By Investing.com
Soleno Therapeutics CFO sells over $298k in company stock…
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi…
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a…
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…